Abstract
Histone deacetylases (HDACs) regulate gene expression by modulating chromatin architecture via histone hypoacetylation. They play a key role in regulating cellular processes including cell cycle arrest and apoptosis. Hyperactivity of HDACs plays a key role in tumour onset and progression making these enzymes as striking targets for anticancer drugs and therapy. Certain cancers are associated with upregulation of specific class II HDAC isoform rather than multiple ones. Therapeutic intervention using small-molecules namely histone deacetylase inhibitors (HDACi), often targets many isoforms unselectively (pan-HDACi) due to structural identity culminating in debilitating off-target effects and reduced in vivo potency. This emphasizes the escalating need for developing isoform-selective inhibitors against the defined class of HDACs. Despite the safe and elevated therapeutic benefit, the design of such inhibitors has been challenging. The present article provides intricate details about the role of class II HDAC isoforms in fuelling distinct cancers and the current challenges with the use of pan-HDAC inhibitors in anticancer therapy. The article also highlights the diverse synthetic and in silico approaches taken by scientific community towards the designing of isoform-selective inhibitors against class II HDAC isoforms. The strategies discussed in this review will provide further impetus to the ongoing research regarding the designing of isoform-selective inhibitors for safe and effective anticancer therapy which is today’s need.
Keywords: Histone deacetylases, Histone deacetylase inhibitors, Pan-inhibitors, Isoform-selective inhibitors, Cancer.
Current Topics in Medicinal Chemistry
Title:Novel Approaches Towards Designing of Isoform-Selective Inhibitors Against Class II Histone Deacetylases: The Acute Requirement for Targetted Anticancer Therapy
Volume: 16 Issue: 22
Author(s): Shabir Ahmad Ganai
Affiliation:
Keywords: Histone deacetylases, Histone deacetylase inhibitors, Pan-inhibitors, Isoform-selective inhibitors, Cancer.
Abstract: Histone deacetylases (HDACs) regulate gene expression by modulating chromatin architecture via histone hypoacetylation. They play a key role in regulating cellular processes including cell cycle arrest and apoptosis. Hyperactivity of HDACs plays a key role in tumour onset and progression making these enzymes as striking targets for anticancer drugs and therapy. Certain cancers are associated with upregulation of specific class II HDAC isoform rather than multiple ones. Therapeutic intervention using small-molecules namely histone deacetylase inhibitors (HDACi), often targets many isoforms unselectively (pan-HDACi) due to structural identity culminating in debilitating off-target effects and reduced in vivo potency. This emphasizes the escalating need for developing isoform-selective inhibitors against the defined class of HDACs. Despite the safe and elevated therapeutic benefit, the design of such inhibitors has been challenging. The present article provides intricate details about the role of class II HDAC isoforms in fuelling distinct cancers and the current challenges with the use of pan-HDAC inhibitors in anticancer therapy. The article also highlights the diverse synthetic and in silico approaches taken by scientific community towards the designing of isoform-selective inhibitors against class II HDAC isoforms. The strategies discussed in this review will provide further impetus to the ongoing research regarding the designing of isoform-selective inhibitors for safe and effective anticancer therapy which is today’s need.
Export Options
About this article
Cite this article as:
Ganai Ahmad Shabir, Novel Approaches Towards Designing of Isoform-Selective Inhibitors Against Class II Histone Deacetylases: The Acute Requirement for Targetted Anticancer Therapy, Current Topics in Medicinal Chemistry 2016; 16 (22) . https://dx.doi.org/10.2174/1568026616666160212122609
DOI https://dx.doi.org/10.2174/1568026616666160212122609 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Epigenetic control of cardiovascular health by nutritional polyphenols involves multiple chromatin-modifying writer-reader-eraser proteins
Current Topics in Medicinal Chemistry Voltage-Gated Sodium Channel Blockers as Immunomodulators
Recent Patents on CNS Drug Discovery (Discontinued) Folate Deficiency and Aberrant Expression of DNA Methyltransferase 1 were Associated with Cervical Cancerization
Current Pharmaceutical Design Low Utility in Colposcopy-directed Biopsies for Non-high Grade Cytological Abnormalities on PAP Smear
Current Women`s Health Reviews Near-infrared Light Responsive Upconversion Nanoparticles for Imaging, Drug Delivery and Therapy of Cancers
Current Nanoscience Functionalized Nanocarriers for Enhanced Bioactive Delivery to Squamous Cell Carcinomas: Targeting Approaches and Related Biopharmaceutical Aspects
Current Pharmaceutical Design Anticancer Effects of Ginsenoside Rh2: A Systematic Review
Current Molecular Pharmacology Pharmaceutical Applications of Graphene-based Nanosheets
Current Pharmaceutical Biotechnology Mechanisms of Action of Anesthetics for the Modulation of Perioperative Thrombosis: Evidence for Immune Mechanisms from Basic and Clinical Studies
Current Pharmaceutical Design Regulators of Stem Cells Proliferation in Tissue Regeneration
Current Stem Cell Research & Therapy Oncogene Suppression by Small Interfering RNAs
Current Pharmaceutical Biotechnology An Efficient Prediction of HPV Genotypes from Partial Coding Sequences by Chaos Game Representation and Fuzzy k-Nearest Neighbor Technique
Current Bioinformatics Recent Advances in Phenanthroindolizidine and Phenanthroquinolizidine Derivatives with Anticancer Activities
Anti-Cancer Agents in Medicinal Chemistry Stem Cell-Mediated Exon Skipping of the Dystrophin Gene by the Bystander Effect
Current Gene Therapy Current Protein-based Anti-angiogenic Therapeutics
Mini-Reviews in Medicinal Chemistry HIF-1 Inhibitors for Cancer Therapy: From Gene Expression to Drug Discovery
Current Pharmaceutical Design Cancer Immunotherapy: Battling Tumors with Gene Vaccines
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Oncolytic Viruses: Programmable Tumour Hunters
Current Gene Therapy Evasion of Ribonuclease Inhibitor as a Determinant of Ribonuclease Cytotoxicity
Current Pharmaceutical Biotechnology Budesonide and Phenethyl Isothiocyanate Attenuate DNA Damage in Bronchoalveolar Lavage Cells of Mice Exposed to Environmental Cigarette Smoke
Current Cancer Drug Targets